DOCU · Analyze — Financebot

Date: 2026-05-06 | Sector: Technology — Software Application | Price: ~$46.53 | Market Cap: $9.04B

Position Context

A portfolio-specific passage was removed from the public build.

Position is tiny (~$279 total value). Not a meaningful drag or opportunity at current size.

Phase 1 — Fundamentals Analyst

Revenue

Year (Jan 31)	Revenue	YoY Growth	Gross Profit	Gross Margin
FY2023	$2.516B	—	$1.980B	78.7%
FY2024	$2.762B	+9.8%	$2.189B	79.3%
FY2025	$2.977B	+7.8%	$2.355B	79.1%
FY2026	$3.220B	+8.2%	$2.556B	79.4%
FY2027E	~$3.42B	~+6%	—	—

3yr Revenue CAGR (FY2023→FY2026): 8.6% — decelerating badly from pandemic-era 30-50% growth. Growth is now sub-10% and guidance implies further deceleration.

Gross margins are extremely stable at ~79%. World-class for software, reflects durable pricing power on existing subscription base.

Operating Profitability (GAAP)

Year	Op Income	Op Margin	EBITDA	Net Income
FY2023	-$60M	-2.4%	$3M	-$97M
FY2024	$62M	+2.2%	$196M	$74M
FY2025	$230M	+7.7%	$357M	$1,068M*
FY2026	$299M	+9.3%	$466M	$309M

*FY2025 net income inflated by ~$840M deferred tax asset recognition — not recurring. Normalized net income ~$248M.

Operating leverage is real: margins improved ~11.7 percentage points in 3 years. But GAAP margins remain depressed by SBC.

FCF and the SBC Adjustment — Critical Finding

Year	Op CF	CapEx	Reported FCF	FCF Margin	SBC	SBC-Adj FCF	Adj Margin
FY2023	$507M	-$78M	$429M	17.1%	$539M	-$110M	neg
FY2024	$980M	-$92M	$887M	32.1%	$617M	$270M	9.8%
FY2025	$1,017M	-$97M	$920M	30.9%	$610M	$310M	10.4%
FY2026	$1,165M	-$106M	$1,059M	32.9%	$622M	$437M	13.6%

Reported FCF 3yr CAGR: ~34.9% (FY2023 was depressed; 2yr FY2024→FY2026: +9.3%) SBC-adjusted FCF 2yr CAGR: +27.2% (FY2024→FY2026) — improving but from a near-zero base

The watchlist's "27%+ FCF CAGR" was based on reported FCF, which overstates true economic earnings. SBC of $622M consumes 58.7% of reported FCF. On SBC-adjusted terms, DocuSign generates $437M in true owner earnings — a $13.6% adjusted FCF margin. Respectable for a maturing SaaS company, but not the 33% FCF machine the headline numbers suggest.

SBC as % of revenue is declining (21.4% → 19.3% over 3 years) — a positive trend that deserves monitoring. If SBC falls to 15% of revenue at $3.8B revenue (FY2028), adjusted FCF would approach ~$700M+ at maintained margins.

Shares Outstanding & Buyback Efficiency

Year	Shares (period-end)	Diluted Avg	Buybacks
FY2023	201.9M	200.9M	$63M
FY2024	205.3M	208.9M	$146M
FY2025	202.5M	210.3M	$684M
FY2026	197.8M	209.1M	$869M

$1.76B in buybacks over 4 years yielded only a 4.1M net share reduction (2%). SBC issuance is fighting buybacks almost dollar-for-dollar. New $2B buyback authorization announced in Q4 FY2026 should accelerate this if SBC doesn't also ramp.

This is not capital return — it's SBC offset. The true net shareholder return from buybacks is minimal.

Capital Allocation

FY2026 Use	Amount	% of FCF
Share repurchases	$869M	82%
M&A	$0	0%
Debt repayment	$0	0%
Dividends	$0	0%
Net cash build (decline)	-$97M change	—

Capital allocation is simple: 100% to buybacks. R&D at $665M is an operating expense (not captured here) but represents the growth investment bet on IAM.

Balance Sheet

Metric	FY2026
Total Assets	$4.230B
Financial Debt	$0 (zero long-term financial debt)
Capital Lease Obligations	$185M
Cash + ST Investments	$866M
Other Investments (AFS)	$208M
Total Liquidity	$1.074B
Common Equity	$1.918B
Deferred Revenue (current)	$1.631B
Net Debt	Net Cash — effectively zero

Financial debt: ZERO. The $2.312B in total liabilities is dominated by deferred revenue ($1.661B) — a liability that represents contracted future revenue, not financial risk. The balance sheet is clean and conservative.

Debt-to-assets (financial only): 4.4% (capital leases only). Total liabilities/assets of 54.7% is misleading due to deferred revenue.

Per Share Metrics

Metric	FY2026
Revenue/share	$16.10
Reported FCF/share	$5.35
SBC-adjusted FCF/share	$2.19
GAAP EPS (diluted)	$1.48
Book value/share	$9.70
Cash/share	$5.43

ROIC Estimate

NOPAT: $350M EBIT × (1 - 0.11 effective tax) = ~$311M
Invested Capital: Equity $1.918B + Debt $185M - Cash $1.074B = $1.029B
ROIC: ~30% — strong, reflects asset-light business model with durable pricing power

Phase 1 — Sentiment Analyst

Q4 FY2026 Earnings (Reported ~March 2026)

Metric	Result	vs. Estimate
Q4 Revenue	$837M	Beat ($827.9M est.)
Q4 EPS (GAAP)	$1.01	Beat ($0.95 est.)
Annual ARR	$3.27B	+8% YoY
Billings	>$1B	Record (first time)
Full-year FCF	>$1B	Beat

The headline beat masked a disappointing guide. FY2027 revenue guidance of ~$3.42B (+6%) fell below the ~10% growth threshold investors expected. Multiple analysts cut price targets following results despite the Q4 beat. Citi downgraded to Neutral with a $50 target in April 2026.

CEO Allan Thygesen Commentary

Described FY2026 as "defined by consistent execution." FY2027 priorities: 1. Growing IAM — helping customers automate workflows via direct sales, partners, and product-led growth 2. Expanding AI data advantage through DocuSign Iris (proprietary model trained on billions of agreements) 3. New $2B buyback authorization signals confidence in cash generation

IAM currently at 11% of ARR ($350M in Q4) with a stated target of 18% of total revenue ($600M+) by end of FY2027. This is the key growth catalyst to watch.

Competitive News & Disruption Threats

OpenAI DocuGPT (Sept 2025): OpenAI unveiled an AI product targeting document understanding, data extraction, and agreement automation — directly threatening DocuSign's IAM expansion. This was the primary catalyst for the Sept-Jan stock collapse from $94 → $45. The threat is real but not yet proven at enterprise scale.

Microsoft + Adobe: Both continue to bundle document and signing capabilities into existing enterprise suites. Microsoft's scale ($305B trailing revenue, 47% op margins) makes it the most dangerous long-term threat. Adobe Sign is the most direct competitor for e-signature.

Competitive moat under siege but not broken. DocuSign still processes billions of agreements annually. "Just DocuSign it" remains cultural shorthand — brand equity that takes years to erode.

Institutional & Insider Sentiment

Institutional ownership: ~87% — widely held by large funds
Insider activity: Net selling. Significant insider sales in Jan and March 2026. No material insider buying reported. This is a yellow flag — management is not buying at these prices despite the stated "execution confidence."
Analyst consensus: 3 Strong Buy / 3 Buy / 15 Hold / 0 Sell / 1 Strong Sell. Predominantly neutral. The market is in "show me" mode on IAM.

Stock Trajectory

Period	Price	Event
Nov 2021 ATH	~$314	Pandemic peak
Jan 2026	~$97	Pre-collapse
Sept 2025	~$72	DocuGPT announcement shock
Feb 2026	~$45	52-wk low zone
Current	~$46.53	85% off ATH, near floor

The stock is down 52% since Jan 2026 and 85% from ATH. A lot of bad news is priced in.

Phase 1/2 — Moat Analyst

Moat Sources

Source	Strength	Assessment
Brand / verbification	Strong	"DocuSign it" = durable top-of-mind. Years to displace.
Network effects	Moderate	Bilateral agreement networks create switching friction
Switching costs	Strong	Embedded workflows, compliance trails, integrations (Salesforce, SAP, Workday, etc.) are painful to replace
Data moat (AI)	Emerging	Billions of anonymized agreements → DocuSign Iris proprietary model. Real competitive asset if IAM gets traction.
Regulatory compliance	Moderate	ESIGN Act, eIDAS (EU) compliance embedded in product reduces enterprise DIY risk

ROIC + Gross Margin Trends

Year	Gross Margin	GAAP Op Margin	Est. ROIC
FY2023	78.7%	-2.4%	~-7%
FY2024	79.3%	+2.2%	~5%
FY2025	79.1%	+7.7%	~20%
FY2026	79.4%	+9.3%	~30%

ROIC improvement is strong and real — the business has real economic returns. Gross margins are stable and elite.

Adversarial Stress Test: How Would a Rival Kill This?

Attack vector 1 — Hyperscaler bundling (MOST DANGEROUS): Microsoft bundles signatures + document AI into M365 Copilot. Free for existing M365 customers removes willingness to pay for DocuSign. This erodes e-signature as a distinct budget line. It doesn't eliminate DocuSign overnight (compliance, audit trails, integrations) but compresses the SMB market over 3-5 years.

Attack vector 2 — AI agents bypassing DocuSign entirely: An AI agent that negotiates and executes agreements autonomously could theoretically bypass document-based signing. DocuSign's value is in the legal non-repudiation layer — which AI agents can still use, but it de-emphasizes the workflow and UI DocuSign charges for.

Attack vector 3 — Point competitor (OpenAI DocuGPT, Adobe): A superior AI-native contract lifecycle management tool that out-features IAM on analysis, drafting, and negotiation — before DocuSign achieves critical mass in the CLM market.

Defense: DocuSign's strongest moat is workflow lock-in + compliance audit trails, not the signing UI. The most defensible moat is the legal infrastructure layer (non-repudiation, timestamping, court admissibility, cross-border compliance) that hyperscalers cannot easily replicate without years of regulatory work. This is the product DocuSign should be selling — and IAM is moving in that direction.

Disruption Forecast

Horizon	Assessment
1-2 years	Moat largely intact. No incumbent has fully displaced e-signature at enterprise. IAM is early traction.
3-5 years	Elevated risk. Microsoft's Copilot integration accelerates. DocuGPT or Adobe AI could take meaningful CLM share if IAM stalls.
5+ years	High uncertainty. If AI agents handle agreement workflows end-to-end, DocuSign's value is reduced to a compliance utility — lower multiple, lower growth.

Evergreen Rating: 6/10 — Not a forever hold at current business model. IAM execution in the next 18 months is the swing factor.

Phase 2 — Valuation Analyst

No dividend — DDM and DYT are not applicable.

Graham's Intrinsic Value

√(22.5 × GAAP EPS × BVPS) = √(22.5 × $1.48 × $9.70) = √(323) = $17.97

Far below current price. Graham's formula is not appropriate for asset-light software companies with high intangibles. The low book value and GAAP-depressed EPS produce a nonsensical result here. Not weighted in verdict.

Bogle Expected Return Framework

Dividend yield: 0% (no dividend)
Earnings/FCF growth: 8-10% base case; 12-15% bull (IAM re-acceleration)
P/E multiple change: Fwd P/E currently 9.24x non-GAAP. Historical SaaS range 15-25x
Re-rate to 15x: +62% multiple expansion over 5 years = ~10% p.a.
Stays at 9x: 0% multiple contribution

Scenario	Growth	Multiple Expansion	Total Expected Return
Bear (stagnation)	5%	0%	~5% p.a.
Base (IAM slow ramp)	8%	+4% p.a. (→13x)	~12% p.a.
Bull (IAM acceleration)	14%	+8% p.a. (→15x)	~22% p.a.

FCF-Based Fair Value

Basis	FCF	Multiple	Implied Equity Value	Per Share
Reported FCF	$1.059B	12x	$12.7B + $1.1B cash	$70-75
SBC-adjusted FCF	$437M	20x	$8.7B + $1.1B cash	$49-53
SBC-adj FCF (bull, 10% growth x5yr)	~$700M	18x	$12.6B + $1.1B cash	$69-73

Summary Valuation

Metric	Value	Assessment
Current Price	$46.53	—
P/FCF (reported)	8.5x	Historically cheap for quality SaaS
P/Adj-FCF (SBC)	20.7x	Reasonable; not screaming cheap
Fwd P/E (non-GAAP)	9.24x	Very cheap on non-GAAP basis
EV/Revenue	2.5x	Compressed — growth penalty
Base Fair Value	$50-60	Modest upside at current price
Bull Fair Value	$75-90	IAM hits target, multiple re-rates
Bear Floor	$35-40	AI disruption accelerates, growth falls to <5%

At $46.53, the stock is trading at the low end of base fair value. Meaningful upside exists but requires IAM execution. The downside is limited (strong FCF floor, zero debt) but not zero.

Phase 3 — Conflict Resolution

Tension: Moat Analyst (cautious on disruption) vs. Valuation Analyst (sees cheap entry)

Fundamentals says: FCF is real, margins are improving, balance sheet is clean. Moat says: The moat is under genuine AI-driven threat, and IAM is unproven at scale. Valuation says: At 9x fwd P/E and 8.5x P/FCF, a lot of disruption is already priced in.

Resolution: Both are right for different scenarios. The stock is cheap relative to current fundamentals but priced as a value trap if growth stagnates. The debate resolves to: what is the probability of IAM re-accelerating growth above 10%? This is a "show me" thesis, not a conviction buy.

Weighting for mature SaaS under competitive pressure: Fundamentals + Valuation > Moat. The cash generation is real and undeniable. The moat threats are real but multi-year in playing out. The valuation discount is sufficient to own a small-to-moderate position.

Phase 4 — Manager Synthesis

Weighted Verdict

A portfolio-specific passage was removed from the public build.

The investment case rests on three pillars:

FCF floor: Even in a bear case, DocuSign generates $400-900M+ in FCF (reported/adjusted) on a $9B market cap. The downside is cushioned.
IAM option value: If IAM reaches 18% of revenue in FY2027 and grows to 30%+ by FY2028, total revenue growth re-accelerates to 12-15%, and a 15x fwd P/E re-rating gives a ~$80-90 stock. This is plausible but not guaranteed.
Valuation discount: 9x non-GAAP fwd P/E and 8.5x reported P/FCF are genuinely cheap for a company with 79% gross margins, 30% ROIC, and zero financial debt. At these levels, you're paying almost nothing for the IAM option.

Key Risks

Risk	Severity	Probability	Flag
OpenAI DocuGPT gains enterprise traction	High	Medium	🟡 Monitor
Microsoft bundles agreement AI into Copilot at scale	High	Medium	🟡 Monitor
IAM stalls below 12% of ARR	Medium	Medium	🔴 Thesis break
Insider selling signals management pessimism	Medium	Low	🟡 Yellow flag
SBC fails to decline as % of revenue	Low	Low	🟡 Monitor

IAM Monitoring Framework

Milestone	Action
IAM reaches 15%+ of ARR by Q2 FY2027	Upgrade conviction → consider adding shares
IAM still at 11-12% by Q4 FY2027	Downgrade conviction → consider trimming
IAM >18% of ARR + revenue growth >12%	Bull thesis confirming → hold/add aggressively
IAM declines or competition displaces a major customer	Thesis break → exit

A portfolio-specific passage was removed from the public build.

Final Verdict

Dimension	Score
Financial Health	7.5/10
Moat Durability	5.5/10
Valuation	7.0/10
Sentiment & Execution	6.0/10
Overall Conviction	6.5/10

Action: HOLD. Do not add at $46.53 (borderline outside the $40-46 add zone). Add if dips to $40-43. Do not trim — position is too small to matter. Watch IAM % of ARR as primary thesis indicator. Next catalyst: Q1 FY2027 earnings (likely June 2026).

Price Zone	Action
$35-40	Add aggressively — deep in value
$40-43	Add — in buy zone
$43-50	Hold — borderline
$50-65	Hold — let IAM prove itself
$65-80	Trim 25-50% into strength
$80+	Evaluate — near bull fair value